Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) Quarterly Sentiment Report

June 14, 2018 - By Linda Rogers

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Logo

Sentiment for Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) institutional sentiment decreased to 1.05 in Q1 2018. Its down -0.14, from 1.19 in 2017Q4. The ratio dropped, as 40 hedge funds started new and increased positions, while 38 trimmed and sold stakes in Tetraphase Pharmaceuticals Inc. The hedge funds in our partner’s database now have: 19.93 million shares, down from 29.51 million shares in 2017Q4. Also, the number of hedge funds holding Tetraphase Pharmaceuticals Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 15 Reduced: 23 Increased: 27 New Position: 13.

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company has market cap of $219.43 million. The Company’s lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It currently has negative earnings. The firm has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy.

The stock increased 6.78% or $0.27 during the last trading session, reaching $4.25. About 1.70 million shares traded or 120.28% up from the average. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has declined 48.55% since June 14, 2017 and is downtrending. It has underperformed by 61.12% the S&P500.

Analysts await Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) to report earnings on August, 1. They expect $-0.36 EPS, up 56.63 % or $0.47 from last year’s $-0.83 per share. After $-0.42 actual EPS reported by Tetraphase Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -14.29 % EPS growth.

Broadfin Capital Llc holds 0.5% of its portfolio in Tetraphase Pharmaceuticals, Inc. for 1.05 million shares. 683 Capital Management Llc owns 600,000 shares or 0.16% of their US portfolio. Moreover, Tekla Capital Management Llc has 0.1% invested in the company for 859,322 shares. The Michigan-based Dow Chemical Co De has invested 0.07% in the stock. A.R.T. Advisors Llc, a New York-based fund reported 262,896 shares.

Since January 1, 0001, it had 0 insider purchases, and 2 sales for $98,932 activity.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Ratings Coverage

Ratings analysis reveals 83% of Tetraphase Pharmaceutical’s analysts are positive. Out of 6 Wall Street analysts rating Tetraphase Pharmaceutical, 5 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $3 while the high is $11. The stock’s average target of $7.20 is 69.41% above today’s ($4.25) share price. TTPH was included in 12 notes of analysts from February 12, 2018. The stock has “Market Perform” rating by BMO Capital Markets on Wednesday, February 14. On Wednesday, February 21 the stock rating was maintained by FBR Capital with “Buy”. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) earned “Buy” rating by FBR Capital on Wednesday, March 7. The stock has “Buy” rating by SunTrust on Wednesday, February 14. On Monday, February 12 the stock rating was initiated by FBR Capital with “Buy”. The firm has “Buy” rating by FBR Capital given on Monday, June 4. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) earned “Buy” rating by Gabelli on Thursday, March 29. FBR Capital maintained the shares of TTPH in report on Monday, June 11 with “Buy” rating. BMO Capital Markets maintained it with “Market Perform” rating and $3 target in Thursday, March 8 report. The firm has “Buy” rating by FBR Capital given on Tuesday, February 27.

More notable recent Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) news were published by: Benzinga.com which released: “31 Stocks Moving In Thursday’s Mid-Day Session” on June 14, 2018, also Benzinga.com with their article: “32 Stocks Moving In Monday’s Mid-Day Session” published on June 11, 2018, Nasdaq.com published: “Tetraphase Pharmaceuticals to Present Eravacycline and TP-6076 Data at ASM Microbe 2018” on May 21, 2018. More interesting news about Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) were released by: Benzinga.com and their article: “21 Stocks Moving In Monday’s Pre-Market Session” published on June 11, 2018 as well as Benzinga.com‘s news article titled: “23 Stocks Moving In Thursday’s Pre-Market Session” with publication date: June 14, 2018.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: